Clinical trials: Refractory Crohn's Disease
Crohn's Disease (CD), Ulcerative Colitis (UC)
Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis
This single-center, retrospective study aims to evaluate the effectiveness and safety of upadacitinib (UPA) in Asian pediatric patients with refractory Crohn's disease (CD) and elderly patients with refractory ulcerative colitis…
- Conditions
- Crohn's Disease (CD), Ulcerative Colitis (UC), Refractory Crohn's Disease, Refractory Ulcerative Colitis
- Trial name
- UPA-AGE (NCT06922331)
- Testing
- Upadacitinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Crohn's Disease Aggravated, Crohn's Disease in Remission
Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study
Crohn's disease is a chronic inflammatory bowel disorder characterized primarily by abdominal pain and diarrhea [1,2]. Conventional treatments include corticosteroids and immunosuppressants (such as azathioprine, mercaptopurine…
- Trial name
- NCT07149467
- Testing
- Ustekinumab (approximately 6 mg/kg), Upadacitinib
- Volunteers
- 454 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University